Akero Therapeutics 2025年第一季度每股收益$（0.90）击败$（0.99）估计、现金、现金等值以及短期和长期有价证券截至2025年3月31日，为11.28亿美元，足以为其截至2028年的当前运营计划提供资金

2025-05-12 19:20

Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX)
Presented two oral presentations and a poster presentation highlighting the latest data and new analyses from 96-week SYMMETRY and HARMONY clinical studies at EASL Congress 2025
SYMMETRY study results published in New England Journal of Medicine
Raised $402.5 million in gross proceeds in a follow-on public offering in January 2025, resulting in reserves of cash, cash equivalents, and marketable securities of $1,128 million at March 31, 2025